The pharmaceutical company said Tuesday the FDA's Oncologic Drugs Advisory Committee voted 6-2 in favor of Darzalex Faspro, or daratumumab and hyaluronidase-fihj, to treat adult patients with ...

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do/do not ...

In an interview with Targeted Oncology, C. Ola Langren, MD, discussed the continuing impact of the groundbreaking FDA ODAC ...

University of Texas at Dallas bioengineers, in collaboration with UT Southwestern Medical Center researchers, are developing an enhanced light-activated immunotherapy approach that could one day treat ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, ...

Patients with lower physical function before starting daratumumab therapy showed greater treatment benefit than those who ...

Rising prevalence, aging populations, and therapeutic innovation are reshaping the landscape of multiple myeloma care and ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM) drug, ...

Investors are closely monitoring the performance of Indian pharma companies in the March 2025 quarter and their ability to ...